Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are trading higher in Monday’s after-hours session after the company scheduled a Phase 3 trial results readout for this week.
- Amylyx Pharmaceuticals shares are testing new highs. What’s driving AMLX to record levels?
Amylyx Pharma Announces Phase 3 LUCIDITY Results Date
Amylyx Pharmaceuticals said it will announce the top-line results for its Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) Tuesday morning. Senior management will hold a conference call at 8 a.m. ET to discuss results from the trial.
Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with FDA Breakthrough Therapy Designation in PBH.
The trial enrolled 78 participants over 16 weeks as a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery.
The last participant was randomized and dosed in the Phase 3 clinical trial in March. If approved, commercial launch of avexitide is anticipated in 2027.
AMLX Shares Surge After the Close
AMLX Price Action: Amylyx shares were up 15.73% in after-hours Monday, trading at $24.80 at the time of publication, according to Benzinga Pro.
Image: Shutterstock.com
